Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Healthcare System
• Collaborator: Genentech, Inc.
• Treatments: Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

1. Age > 18 years

2. Symptomatic pleural effusion requiring intervention

3. Expected survival > 3 months

4. Written informed consent to trial participation

Exclusion Criteria:

1. Females who are pregnant or lactating

2. Inability to obtain consent from the patient or patient's designated representative.

3. Inability of the patient to comply with the protocol.

4. Previously documented adverse reaction to talc or cathflo activase.

5. Oral or intravenous steroid therapy